The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects

BACKGROUND: Famitinib is an oral, small-molecule, multi-targeted tyrosine kinase inhibitor under clinical investigation for the treatment of solid tumors. As famitinib is metabolized mainly by cytochrome P450 3A4 (CYP3A4), the study was conducted to investigate the effect of potent CYP3A4 inducer ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ting, Li, Xin, Jiang, Xin, Wang, Chenjing, Sun, Feifei, Liu, Yanping, Lin, Pingping, Shi, Ping, Fu, Yao, Gao, Xiaomeng, Zhang, Yanyan, Cao, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556364/
https://www.ncbi.nlm.nih.gov/pubmed/36107220
http://dx.doi.org/10.1007/s00280-022-04474-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556364/
https://www.ncbi.nlm.nih.gov/pubmed/36107220
http://dx.doi.org/10.1007/s00280-022-04474-8

Ejemplares similares